携带HIV-1抗原的单纯疱疹病毒载体疫苗的构建及鉴定

利用细菌人工染色体技术将串联的HIV-1 gp160、gag和protease基因以及表达元件插入1型单纯疱疹病毒(Herpes simplex virus type 1,HSV-1)内部反向重复序列区,以获得携带HIV-1抗原的单纯疱疹病毒载体疫苗。首先将HIV-1 gp160(B型和C型)、gag和protease基因串联克隆入pc DNA3获得重组质粒pc DNA/g Bgp和pc DNA/g Cgp,重组质粒转染293FT细胞,Western blotting检测HIV抗原表达。继而将pc DNA/g Bgp和pc DNA/g Cgp中包括HIV-1抗原基因和表达元件的表达框克隆入p KO5/BN获得重组穿梭质粒p KO5/BN/g Bgp和p KO5/BN/g Cgp,穿梭质粒电转含BAC-HSV的大肠杆菌,筛选重组菌,提取重组DNA并转染Vero细胞,挑取病毒蚀斑纯化重组病毒,Southern blotting鉴定重组病毒DNA,Western blotting检测重组病毒感染细胞中HIV抗原表达,并分析病毒的增殖特性。结果表明,Western blotting在pc DNA/g Bgp和pc DNA/g Cgp转染的293FT细胞中检测到表达的gp160和gag蛋白。p KO5/BN/g Bgp和p KO5/BN/g Cgp分别电转获得重组菌,并从重组DNA转染的Vero细胞中纯化获得重组HSV,Southern blotting检测表明重组HSV基因组发生特异性重组,重组病毒感染细胞中检测到gp120和gp41,且重组HSV保留了在哺乳动物细胞中的复制能力。本研究获得携载HIV-1 gp160、gag和protease基因的重组HSV,并保留了在哺乳动物细胞中的复制能力,可作为HIV-1复制型病毒载体疫苗。     

单纯疱疹病毒1型载体

本讨论单纯疱疹病毒１型的特点和作为基因治疗载体的单纯疱疹１型载体的构建方法及其应用。     

牛疱疹病毒1型作为活病毒载体的研究进展

牛疱疹病毒1型（BHV1）是牛的易感病毒,作为大分子量DNA病毒,它具有插入并表达外源基因成为活病毒载体的潜力。随着对BHV1分子生物学的深入研究,BHV1已被广泛用于研究宿主范围狭窄而且安全的活病毒载体。     

一种携带人α1bIFN的单纯疱疹病毒载体的构建

为研究用单纯疱疹病毒作为表达细胞因子载体的生物重要性,构建了一种表达人α1b干扰素(IFN)的新型单纯疱疹病毒载体。基于一组含有完整单纯疱疹病毒全基因组的粘粒,α1bIFN表达盒插入到cosmid6上HSV1的UL2基因中,生成cos6-αIFN△UL2。通过将cos6-αIFN/△UL2与cosmid28、cosmid14、cosmid56和cosmid48共转染BHK-21细胞,同源重组产生重组病毒HSV1-αIFN/△UL2。在体外用标准VSV空斑抑制试验检测重组毒感染细胞上清α1bIFN的表达。证实HSV1-αIFN/△UL2感染的细胞中表达的人α1bIFN是有生物活性的。MOI=10感染时,24h后产生2 8×104IU/ml。而对照病毒感染时,这些细胞并不分泌可以检测到的α1bIFN。鉴于HSV1载体的嗜神经性,该载体对于分析体内神经系统局部表达的IFN的抗病毒能力是有用的。     

一种高效的重组腺伴随病毒载体生产系统

重组腺伴随病毒(recombinant adeno-associated virus, rAAV)载体是目前较理想的基因治疗载体之一,但难以大规模制备一直是影响其广泛应用的主要因素.曾组建了一种表达2型腺伴随病毒(adeno-associated virus type 2,AAV-2) Rep和Cap的重组1型单纯疱疹病毒HSV1-rc/DUL2,现在此基础上,证实了该重组病毒支持rAAV的复制与包装,包装出的rAAV具有感染性;构建了携带新霉素抗性基因、适合多种外源基因插入的通用型rAAV载体质粒pSNAV-2及表达绿色荧光蛋白(green fluorescent protein, GFP)的rAAV载体质粒pSNAV-2-GFP,建立了稳定携带GFP基因表达盒的rAAV载体细胞株;确定了HSV1-rc/DUL2感染载体细胞株时的最佳感染复数(multiplicity of infection, MOI)为0.1;采用“一种病毒感染一个载体细胞株”的策略,用“感染”的方式代替传统的“转染”方式,使每个细胞产生的rAAV比传统方式提高了2个数量级以上,并实现了rAAV的规模化制备,为rAAV用于基因治疗的临床试验打下了基础.     

单纯疱疹病毒I型扩增子系列载体的构建

我们先前已报道了构建成一种能在ＨＳＶ ｔｓＫ株辅助下进行复制和包装,并表达β－半乳糖苷酶基因ｌａｃＺ的ＨＳＶ－１扩增子质粒ｐＨＳＬ,以及它的应用。该质料中依次含有ＨＳＶ－１复制起点ｏｒｉＳ序列及ＩＥ６８启动子、ｌａｃＺ基因、ＳＶ４０ｐｏｌｙＡ、ＨＳＶ－１包装信号‘ａ’序列和大肠杆菌质粒骨架。然而,该质粒中的报告基因ｌａｃＺ无法用简单的酶切方法卸载下来,继而装入目的基因。本研究在此基础上,新构建了一     

采用我国痘苗病毒天坛株载体表达单纯疱疹病毒Ⅰ型糖蛋白D

木文从单纯疱疹病毒Ⅰ型(HSV-1)基因组EcoRI H片段中分离出含有糖蛋白D(gD)基因的2.5kb DWA片段,插入带有痘苗病毒天坛株TK基因区段的pJC—2质粒p7.5k启动子的下游,转染TK~-143细胞,获得带有HSV-1 gD基因的重组痘苗病毒。采用HSV-1 gD单克隆抗体免疫胶体金技术进行电镜观察表明,重组痘苗病毒感染的细胞内有特异性HSV-1 gD抗原.重组病毒免疫家兔后6周可产生明显的HSV-1中和抗体。     

一种可切除包装信号的重组1型单纯疱疹病毒的产生

A new kind of recombinant herpes simplex virus type 1 (HSV 1) was constructed. This recombinant, named HSV1 LaL, contained an unique packaging signal (“a" sequence) flanked by two loxP sites in parallel orientation, named LaL, while the original packaging signals of HSV 1 were deleted. Based on a set of cosmids containing the entire HSV 1 genome except the “a" sequence, the LaL was inserted into HSV 1 UL44 gene on one of the cosmids, cos56, generating cos56/LaL. By co transfecting cos56/LaL with the other cosmids, HSV1 LaL was generated in the cells by recombination. By introducing cos56/LaL or HSV1 LaL respectively into E.coli or BHK cells that expressed Cre recombinase, LaLs on both of them were excised by Cre, which was proved by PCR detection. To study the potential use as helper virus in packaging amplicon vector, HSV1 LaL was compared with a control virus HSV1 lacZ that contained a lacZ gene in the UL44 gene. The titer of amplicon virus generated from HSV1 LaL infected BHK/Cre cells was basically the same as that from HSV1 lacZ infected cells, however,the former contained about 10 fold less helper virus than the later, while HSV1 LaL showed the same replication rate as HSV1 lacZ on standard cells, like BHK 21.     

携带GFP绿色荧光标记的重组BAC-HSV-1HF株的构建及其子代病毒的特性研究

本研究旨在构建由细菌人工染色体(Bacteria artificial chromosome,BAC)携带的单纯疱疹I型病毒质粒及携带绿色荧光蛋白(Green fluorescent protein,GFP)的重组型BAC-HSV-1感染性子代病毒。构建了携带HSV-1同源臂的质粒C223-UL43左臂-UL47右臂。将该质粒线性化后与HSV-1基因组共转染至Vero细胞,通过真核细胞内同源重组产生了含有GFP报告基因的BAC-HSV-1重组病毒,噬斑纯化筛选出阳性重组病毒,并再次感染Vero细胞,Hirt法提取BAC-HSV-1环形基因组并将其电穿孔入DH10B感受态细胞,由PCR和酶切法鉴定BAC-HSV-1质粒。为研究BAC-HSV-1子代病毒的生物学特性,将实验组和对照组细胞分别给予BAC-HSV-1质粒和HSV-1基因组DNA,收取病变细胞的上清液,以MOI=0.1再次感染Vero细胞,半数组织培养感染剂量(50% tissue culture infective dose,TCID50)法测定两组的病毒滴度。PCR和酶切法分别鉴定BAC-HSV-1,结果示BAC-HSV-1构建成功。TCID50法测定实验组和对照组病毒滴度,经统计学分析两组病毒滴度间差异无统计学意义(P>0.05)。本研究成功地构建了真核细胞和原核细胞间穿梭的HSV-1-BAC重组病毒/质粒。     

Specific Deposition of Passively Transferred Monoclonal Antibodies against Herpes Simplex Virus Type 1 in Rat Brain Infected with the Virus

The kinetics of human monoclonal antibody (anti-gB) to herpes simplex virus type 1 (HSV-1) were investigated after intravenous injection of anti-gB into an HSV-1 encephalitis animal model. Immunohistochemical study revealed specific deposition of passively tansferred anti-gB in the hippocampus and thalamus of the infected rat brain, and it bound to the same neurons in which HSV-1 antigen was positively stained. To examine the macroscopic distribution of anti-gB in the infected brain, we undertook an ¹²⁵I-labeled anti-gB injection study, and the same distribution of ¹²⁵I-labeled anti-gB deposition was observed by brain semimicroautoradiography as in the immunohistochemical study. These results suggest that anti-gB easily permeates the capillary wall and is deposited in the inflammatory site where HSV-1-specific antigen is detectable. The use of radioisotope-labeled anti-gB injection and external brain imaging could lead to a noninvasive diagnostic tool for the early detection of HSV-1 antigen in cases of suspected HSV-1 encephalitis.     

Effect of Heparin on Hemagglutinin of Herpes Simplex Virus Type 1

Heparin inhibited the hemagglutinin activity of herpes simplex virus (HSV) type 1. The minimal inhibitory concentration of heparin required to inhibit 8 hemagglutination (HA) U of HSV ranged from 0.005 to 0.01 U/ml. Mouse erythrocytes failed to combine with the HA inhibitory factor of heparin. On the other hand, mouse erythrocytes treated with heparinase had greatly reduced agglutinability by HSV. Virus-heparin complex formation was observed by sedimenting heparin with the virus particles.     

Ex Vivo Infection of Murine Epidermis with Herpes Simplex Virus Type 1

To enter its human host, herpes simplex virus type 1 (HSV-1) must overcome the barrier of mucosal surfaces, skin, or cornea. HSV-1 targets keratinocytes during initial entry and establishes a primary infection in the epithelium, which is followed by latent infection of neurons. After reactivation, viruses can become evident at mucocutaneous sites that appear as skin vesicles or mucosal ulcers. How HSV-1 invades skin or mucosa and reaches its receptors is poorly understood. To investigate the invasion route of HSV-1 into epidermal tissue at the cellular level, we established an ex vivo infection model of murine epidermis, which represents the site of primary and recurrent infection in skin. The assay includes the preparation of murine skin. The epidermis is separated from the dermis by dispase II treatment. After floating the epidermal sheets on virus-containing medium, the tissue is fixed and infection can be visualized at various times postinfection by staining infected cells with an antibody against the HSV-1 immediate early protein ICP0. ICP0-expressing cells can be observed in the basal keratinocyte layer already at 1.5 hr postinfection. With longer infection times, infected cells are detected in suprabasal layers, indicating that infection is not restricted to the basal keratinocytes, but the virus spreads to other layers in the tissue. Using epidermal sheets of various mouse models, the infection protocol allows determining the involvement of cellular components that contribute to HSV-1 invasion into tissue. In addition, the assay is suitable to test inhibitors in tissue that interfere with the initial entry steps, cell-to-cell spread and virus production. Here, we describe the ex vivo infection protocol in detail and present our results using nectin-1- or HVEM-deficient mice.     

一种包装AAV2/5的重组单纯疱疹病毒的构建

为了得到一种可以包装AAV2/5和表达绿色荧光蛋白的重组单纯疱疹病毒,设计并构建了一个由AAV2rep基因和AAV5cap基因嵌合而成的rep2cap5基因,然后,利用一套携带HSV1基因组的粘粒系统(cos6、cos28、cos14、cos56、cos48),将rep2cap5基因插入cos6粘粒上HSV1基因组片段的UL2基因中,而将EGFP的表达单位插入cos56粘粒上HSV1基因组片段的UL44基因中,用这2个重组粘粒与其它3个粘粒(cos14、cos28、cos48)共转染BHK-21细胞获得了重组病毒HSV1-r2c5-EGFP并进行了空斑纯化。HSV1-r2c5-EGFP病毒能够在BHK-21细胞连续传代,并且可以观察到几乎所有的感染细胞都能产生绿色荧光。用PCR方法以及Southern杂交方法表明所获得的HSV1-r2c5-EGFP中携带有rep2cap5基因,用HSV1-r2c5-EGFP感染携带报告基因LacZ的AAV载体细胞株,获得了具有感染性的重组AAV2/5-LacZ。结果表明,所获得的重组单纯疱疹病毒HSV1-r2c5-EGFP可提供AAV2/5载体包装所需的全部辅助功能,是一种能简便、高效制备重组AAV2/5病毒的通用性辅助病毒。     

单纯疱疹病毒Ⅰ型新开放读码框UL57的鉴定

单纯疱疹病毒1型(Herpes simplex virus type 1,HSV-1)潜伏感染期间LATs的活跃转录可能与其启动子与增强子两侧的CTCF结合序列有关。本研究对位于UL56下游与LAT启动子上游之间并与CTCF结合序列重叠存在的一个新开放读码框(本研究中命名为UL57)进行了鉴定。首先利用HSV-1(F)细菌人工染色体(HSV-BAC)系统构建重组病毒HSV-EGFP-UL57,将EGFP序列插入UL57 5’端;然后分别通过Northern Blot和Western Blot检测EGFP标记的UL57的转录和表达;同时构建敲除UL57的重组病毒HSV-ΔUL57,观察UL57对病毒增殖的影响。结果显示,重组病毒HSV-EGFP-UL57感染HEp-2细胞17h后,EGFP探针检测到两条转录产物,其中1.8kb转录产物与预测大小相符;使用放线菌酮(Cycloheximide,CHX)阻断病毒即刻早期蛋白/早期蛋白合成后,UL57转录受到明显抑制。重组病毒HSV-EGFP-UL57感染Vero细胞后,9h可见融合蛋白表达,24h表达明显;融合蛋白分子量与预测大小(58kD)一致。病毒生长曲线显示,重组病毒HSV-EGFP-UL57及HSV-ΔUL57在Vero细胞中的增殖水平与HSV-1(F)基本一致。本研究表明,在HSV-1基因组(GenBank:GU734771.1)UL56下游与LAT启动子上游之间存在一个新开放读码框UL57(116 921bp～117 799bp),UL57可以进行转录,且其转录受病毒即刻早期蛋白/早期蛋白调控;转录产物可以翻译出融合蛋白,但表达水平较低。删除UL57对病毒增殖无明显影响。     

栀子提取物ZG对单纯疱疹病毒1型细胞吸附的影响

采用负染技术,借助高倍电子显微镜观察栀子提取物ZG作用后,病毒颗粒及其病毒吸附蛋白(virus attach-ment protein,VAP)的变化,考察药物是否直接改变或破坏病毒包膜蛋白的结构,使其失去感染性;采用异硫氰酸荧光素(fluorescein isothiocyanate,FITC)标记病毒,以肝素钠为参照,借助冷却慢扫描电荷耦合器件荧光成象技术,用Aquacomos软件进行图象分析,以探讨栀子提取物ZG不同加药方式对HSV-1吸附量的影响。结果表明栀子提取物ZG对HSV-1包膜表面的VAP无直接破坏作用,不影响病毒对Hep-2细胞的感染性;先加入肝素钠再进行病毒吸附及肝素钠病毒同时加入培养细胞这两种用药方式可明显减少细胞表面病毒的吸附量;栀子提取物ZG各种不同加药方式均能阻止HSV-1对Hep-2细胞表面的吸附,使病毒吸附量减少。     

An Assay Method for Herpes Simplex Virus Type 1 Seroprevalence Survey—Detection of Antibody in Saliva by Avidin-Biotin Complex Enzyme-Linked Immunosorbent Assay (ABC-ELISA)

To determine whether the avidin-biotin complex enzyme-linked immunosorbent assay (ABC-E) is a potentially useful method for detection of herpes simplex virus type 1 (HSV-1) antibody in saliva, paired serum and saliva samples from 129 healthy individuals aged 18 to 25 years were collected simultaneously and subjected to a neutralization test (NT) for neutralizing antibody and also to an indirect ELISA (IE) and ABC-E for HSV-1 specific IgG detection. Compared with the results of NT, the sensitivities of the IE and ABC-E for serum were both 100% (45/45), and for saliva 82.2% (37/45) and 93.3% (42/45), respectively. The specificity of all these methods was 100% (84/84). With the same ABC-E method, a significant correlation (r=0.66, P < 0.001) between the OD-difference (d-OD) values of positive serum and saliva samples was observed. Furthermore, the consistency of ABC-E for salivary antibody detection was confirmed with the paired serum and saliva samples which were collected from four individuals followed up for eight months. It was clear that the ABC-E method for saliva can be used in place of the NT and ABC-E method for serum for seroprevalence studying of HSV-1 infection.     

Metabolic Fate of [3H]1-β-d-Arabinofuranosyl-5-[(E)-2-bromovinyl]uracil in Herpes Simplex Virus Type 1-Infected Cells

The metabolic fate of 1-β-d -arabinofuranosyl-5-[(E)-2-bromovinyl]uracil (BV-araU) in herpes simplex virus type 1-infected cells was studied using tritium-labeled BV-araU. [³H]BV-araU was selectively taken-up by infected cells. Approximately 10% of the total uptake of [³H]BV-araU was recovered from the acid-insoluble fraction at any time post-infection. Both cellular uptake of [³H]BV-araU and its incorporation into the acid-insoluble fraction increased with increasing incubation time through 8 hr post-infection. Uptake of [³H]BV-araU and its incorporation into the acid-insoluble fraction also increased proportionally to the duration of exposure to [³H]BV-araU. An alkaline sucrose gradient sedimentation analysis revealed that the radioactive DNA obtained from cells pulse-labeled with [³H]BV-araU were small DNA fragments which remained at the top following a chasing period in isotope-free medium, whereas that pulse-labeled with [³H]thymidine was chased to a fraction of high molecular weight DNA. Nuclease P₁ digestion reduced 99% of the [³H]BV-araU-labeled DNA extracted from infected cells to a low molecular weight. Following digestion of [³H]BV-araU-labeled DNA with micrococcal nuclease and spleen exonuclease, all of the radioactivity was recovered as [³H]BV-araU 3′-monophosphate. Thus, BV-araU strongly inhibits the elongation of viral DNA strands as demonstrated by the alkaline sucrose gradient sedimentation analysis, whereas at least a portion of the [³H]BV-araU is incorporated inside viral DNA strands in infected cells.     

In Vitro Selection of Variants of Herpes Simplex Virus Type 1 Which Differ in Cytopathic Changes

To analyze the mechanisms for in vitro emergence of the syncytial variants of herpes simplex virus type 1 (HSV-1), several cell lines were infected with a mixture of equal amounts of two HSV-1 variants, one syncytial and the other non-syncytial, and changes in their relative abundance were monitored during passage. With a combination of two variants of the Miyama strain of HSV-1, the syncytial variant became dominant during passage in Vero, RK-13 and FL cells. On the other hand, the ratios of the two variants remained around 1:1 during the passage in HEp-2, MGC and HEL cells. In another set of variants of the SKO strain of HSV-1, the outcomes were different from those of the Miyama strain in the FL, MGC and HEp-2 cells. The ratios of the two variants remained around 1:1 during passage in FL cells, while the non-syncytial variant became dominant during passage in MGC and HEp-2 cells. In addition, we examined the effects of a complement and interferon-β (IFN-β) on the outcome of the selection. As a result, the complement slowed the selection of a syncytial variant, whereas IFN-β facilitated it.